|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
35,422 |
$2,103,712.58 |
7.25% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
8,893 |
$2,011,240.88 |
6.93% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
17,843 |
$2,008,408.08 |
6.92% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
9,520 |
$1,952,742.40 |
6.73% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,100 |
$1,896,342.00 |
6.53% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
39,951 |
$1,091,061.81 |
3.76% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
73,989 |
$1,089,857.97 |
3.75% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
5,759 |
$1,070,886.05 |
3.69% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,413 |
$1,056,019.68 |
3.64% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
8,426 |
$995,784.68 |
3.43% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
4,819 |
$987,509.48 |
3.40% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
7,416 |
$988,478.64 |
3.40% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,846 |
$981,471.56 |
3.38% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,223 |
$970,539.57 |
3.34% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,630 |
$934,739.80 |
3.22% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,347 |
$666,153.41 |
2.29% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
6,843 |
$658,433.46 |
2.27% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
3,657 |
$482,650.86 |
1.66% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
10,279 |
$471,703.31 |
1.62% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
865 |
$445,388.50 |
1.53% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,127 |
$389,453.70 |
1.34% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
5,449 |
$384,862.87 |
1.33% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
6,318 |
$345,089.16 |
1.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,005 |
$342,392.05 |
1.18% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,630 |
$342,478.60 |
1.18% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
8,380 |
$280,897.60 |
0.97% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,533 |
$251,796.91 |
0.87% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
10,925 |
$247,014.25 |
0.85% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,238 |
$202,731.18 |
0.70% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,100 |
$197,778.00 |
0.68% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,611 |
$185,511.55 |
0.64% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
7,459 |
$182,894.68 |
0.63% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,049 |
$183,177.72 |
0.63% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
766 |
$173,629.22 |
0.60% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,650 |
$174,718.50 |
0.60% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
12,984 |
$169,051.68 |
0.58% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
6,583 |
$168,788.12 |
0.58% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,646 |
$153,621.18 |
0.53% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
2,836 |
$153,796.28 |
0.53% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,250 |
$153,772.50 |
0.53% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
6,591 |
$151,395.27 |
0.52% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
551 |
$150,235.66 |
0.52% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,618 |
$146,202.48 |
0.50% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,663 |
$146,460.41 |
0.50% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
456 |
$140,644.08 |
0.48% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,872 |
$139,988.16 |
0.48% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
2,776 |
$136,357.12 |
0.47% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,186 |
$134,854.80 |
0.46% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
5,633 |
$131,812.20 |
0.45% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,012 |
$129,794.12 |
0.45% |
| US Dollar |
$USD |
|
Other |
80,894 |
$80,894.22 |
0.28% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|